Core Viewpoint - Peijia Medical's TaurusTrio Transcatheter Aortic Valve (TAV) system has received approval from the National Medical Products Administration (NMPA) of China, marking a significant advancement in the treatment of symptomatic severe aortic regurgitation (AR) [1][5]. Company Overview - Peijia Medical, established in 2012 and headquartered in Suzhou, China, focuses on the interventional procedural medical device market, aiming to become a globally recognized platform for treating structural heart and neurovascular diseases [6]. Product Details - The TaurusTrio TAV system is developed under an exclusive license from JenaValve Technology, designed specifically for patients with symptomatic severe aortic regurgitation via transfemoral access [2]. - The system utilizes JenaValve's proprietary locator technology, allowing stable anchoring without the need for calcification, addressing a significant clinical challenge in treating AR [2]. Clinical Results - The one-year clinical results from the TaurusTrio ALTER-AR study showed a technical success rate of 99.1%, with 0% all-cause mortality at 30 days and only 2.6% at one year [3]. - Significant improvements in cardiac function were observed, with 91.7% of patients recovering to NYHA class I/II at six months, and a 0% incidence of moderate or greater paravalvular leak at one year [3]. Market Impact - The approval of TaurusTrio represents a major milestone for Peijia Medical, addressing a significant unmet clinical need for patients with severe AR who are ineligible for surgery [4][5]. - This achievement is expected to enhance the landscape of interventional treatments in China, promoting precision and minimally invasive therapy for AR care [5].